3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
13
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Breast Neoplasms
22
Triple Negative Breast Neoplasms
6
Stomach Neoplasms
6
Neoplasm Metastasis
6
Pancreatic Neoplasms
5
Ovarian Neoplasms
5
Colorectal Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Melanoma
3
Colonic Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Multiple Myeloma
2
Hematologic Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Thrombocytosis
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Interventions
pembrolizumab
13
Paclitaxel
7
Carboplatin
7
Albumin-Bound Paclitaxel
6
130-nm albumin-bound paclitaxel
6
Gemcitabine
5
Capecitabine
5
olaparib
2
liposomal doxorubicin
2
lenvatinib
2
Doxorubicin
2
Cyclophosphamide
2
eribulin
1
efineptakin alfa
1
Vinorelbine
1
Saline Solution
1
Pemetrexed
1
Oxaliplatin
1
Glucose
1
Fluorouracil
1
Epirubicin
1
Docetaxel
1
Cisplatin
1
Bevacizumab
1
Anthracyclines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Oxaliplatin
×
Breast
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled